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Tumor-derived extracellular vesicles (tEVs) are important signals in tumor-host cell communication, yet it remains unclear how endogenously produced tEVs affect the host in different areas of the body. We combined imaging and genetic analysis to track melanoma-derived vesicles at organismal, cellular, and molecular scales to show that endogenous tEVs efficiently disseminate via lymphatics and preferentially bind subcapsular sinus (SCS) CD169 + macrophages in tumor-draining lymph nodes (tdLNs) in mice and humans. The CD169 + macrophage layer physically blocks tEV dissemination but is undermined during tumor progression and by therapeutic agents. A disrupted SCS macrophage barrier enables tEVs to enter the lymph node cortex, interact with B cells, and foster tumor-promoting humoral immunity. Thus, CD169
+ macrophages may act as tumor suppressors by containing tEV spread and ensuing cancer-enhancing immunity.
A lthough cancer is driven by tumor cellendogenous genetic mutations, it is also modulated by tumor cell-exogenous interactions with host components, including immune cells (1) . Tumor-induced host immune system activation can occur both within and away from the tumor stroma and may involve different communication signals, including soluble factors (2) and tumor-derived extracellular vesicles (tEVs) (3). tEVs are key candidate conveyors of information between cancer and host immune cells because they can travel long distances in the body without their contents degrading or diluting. tEVs may transfer surface receptors or intracellular material to different host acceptor cells (4) (5) (6) ; these processes have all been associated with altered antitumor immunity and enhanced cancer progression (7) . Circulating tEVs also have diagnostic and prognostic potential, as they can be used to detect early cancer stages (8) and to predict overall patient survival (4) and treatment responses (9) . Despite increased understanding of tEVs' importance, a critical barrier to progress in the field has been our limited ability to assess the impact of vesicles that are produced in vivo (7) . To shift current experimental research on tEV-host cell interactions, we combined imaging and genetic approaches to track endogenously produced tEVs and their targets at different resolutions and scales.
We assessed the whole-body biodistribution of tumor-derived material in mice bearing genetically modified B16F10 melanoma tumors (B16F10-mGLuc), which produce tEVs carrying membrane-bound Gaussia luciferase (mGLuc) (10) (fig. S1 ). Quantification of tEV-bound mGLuc activity in various tissues from B16F10-mGLuc + tumor-bearing mice not only confirmed that B16F10-mGLuc + -derived tEVs can exit the tumor stroma and relocate to remote organs but also identified the highest relative mGLuc activity in tumor-draining lymph nodes (tdLNs) when compared to blood, spleen, bone, lung, liver, non-tumor-draining LNs (ndLNs), and other tissues (Fig. 1A and fig. S2A ). Consistently, we measured higher mGLuc signal in lymph than in plasma ( fig. S2B ). Control tumors expressing secreted Gaussia luciferase (sGLuc) did not generate bioluminescence activity in tdLNs ( fig. S2C ).
To decipher endogenous tEVs' interactions in tdLNs at the cellular level, we investigated mice bearing genetically modified B16F10 melanoma cells expressing two membrane-bound reporters:
the vesicular membrane-associated protein CD63 fused with enhanced green fluorescent protein (CD63-eGFP), and the ubiquitous transmembrane marker dLNGFR (truncated receptor for nerve growth factor) ( fig. S3 ). Flow cytometry-based analyses revealed dLNGFR + cells in tdLNs but not in ndLNs (Fig. 1B) . These tdLNs did not include tumor cells or tumor cell apoptotic bodies (figs. S4 to S6 (Fig. 1D and fig. S7 ). Multiphoton microscopy and threedimensional reconstructions of tEV distribution confirmed CD169 + SCS macrophages as a major host cell type interacting with CD63-eGFP + tEVs in vivo (Fig. 1E and figs. S8 and S9) . The vesicles accumulated principally between 10 and 20 mm below the LN capsule and adjacent to CD169 + SCS macrophages, which occupy the space between 20 and 80 mm below the capsule.
We asked whether CD169 + SCS macrophages originate from the tumor stroma, where they may initially capture tEVs. B16F10 tumors were implanted in mice ubiquitously expressing the photoconvertible protein Kaede (12) , and the tumor site was exposed to ultraviolet light in order to shift Kaede fluorescence emission from green to red selectively in tumor-infiltrating host cells (fig. S10, A and B). The tdLN SCS macrophages remained green 24 hours later and therefore did not originate from the tumor stroma ( fig. S10C ). Photoconverted cells in tdLNs were mostly CD103 + DCs ( fig. S10D ). These migratory cells might not be involved in carrying tEVs to LNs, because analysis of lymph collected from B16F10-mGLuc tumorbearing mice revealed mGLuc activity that was higher by a factor of >10 4 in cell-free fractions than in cells from lymph (Fig. 1F) . These data suggest that tEVs freely disseminate to tdLNs, where they preferentially bind resident SCS macrophages.
To define our findings' relevance for human disease, we examined cancer-free sentinel LN (CF-SLN) biopsies from 13 melanoma patients (table S1). Melanin pigment staining was found selectively in macrophage-like populations (figs. S11 and S12, A to C). We then assessed melanomaderived material by staining CF-SLNs with the monoclonal antibody (mAb) clone HMB-45, which is used to pathologically evaluate melanoma metastasis in regional SLNs. HMB-45 reacts with a transmembrane glycoprotein that is part of the gp100 pre-melanosome complex and is expressed by >80% of melanomas (13) . Although the SLNs analyzed were melanoma-free (i.e., stage N0), we identified HMB-45 + cells that corresponded to macrophages morphologically and resided mostly near the LN capsule ( Fig. 2A and fig. S12D ). Serial staining of CF-SLN sections for HMB-45 and the macrophage marker CD68 confirmed that the observed HMB-45 + cells were CD68 + macrophages (Fig. 2B and fig. S13 ). To interrogate the temporal course of HMB-45 + signal appearance during melanoma progression, we assessed CF-SLNs from patients with distinct clinical stages based on Breslow's thickness (tumor depths ranging from <1 mm to >4 mm). We identified HMB-45 + macrophages in >90% of patients independent of tumor progression (Fig. 2, C and D) , which suggests that melanoma-derived material reaches SLNs early in cancer progression, similar to our observations in mice ( fig. S14) .
Given expression in the target cell. Analysis of B16F10-Cre + tumor-bearing mice identified Cre-induced YFP expression in tumor-associated macrophages (TAMs); however, tdLN CD169 + SCS macrophages (and all other tdLN cells) remained exclusively YFP - (Fig. 3, A and B, and fig. S15F ). Thus, on their own, endogenous tEVs are unlikely to modulate SCS macrophages through horizontal transfer. Because SCS macrophage-tEV interactions may regulate tumor progression independently from horizontal transfer, we assessed whether modulating SCS macrophages and/or tEVs affects cancer growth in vivo. We examined Cd169
Dtr/Wt knock-in mice in which CD169 + LN macrophages were specifically depleted by diphtheria toxin (DT) injection (figs. S16 and S17). CD169 + LN macrophage removal significantly enhanced B16F10 tumor growth (Fig. 3C) . Similarly, specifically depleting CD169 + LN macrophages by subcutaneous administration of clodronate liposomes (figs. S18 and S19) accelerated B16F10 tumor progression in wild-type mice (Fig. 3D) . Thus, CD169
+ LN macrophages act as "tumor suppressors" in orthotopic B16F10 melanoma; these findings were extended to orthotopic B16F1 melanoma (Fig. 3E ) and KP lung adenocarcinoma (Fig. 3F ).
To assess whether interactions between endogenous tEVs and SCS macrophages affect tumor progression, we introduced a single copy of either (Fig.  3G) . The observation that enhanced tumor growth from SCS macrophage ablation only occurs in the context of sufficient tEV production supports a causal link between SCS macrophage-tEV interaction and tumor growth.
We then asked whether cancer disrupts SCS macrophage network organization, because pathogens entering LNs can induce such alterations (15) . Three-dimensional multiphoton imaging of tdLNs revealed a decrease in CD169 + SCS macrophage density as soon as day 6 after tumor challenge (Fig. 3H ). This may happen because tdLNs enlarge without expanding their SCS macrophage pool, as indicated by photoconversion ( fig. S10) , parabiosis ( fig. S21A ), 5-bromo-2′-deoxyuridine (BrdU; fig. S21B ), and Ki67 labeling studies ( fig.   S21C ). These results imply different ontogenesis for TAMs and SCS macrophages because, unlike SCS macrophages, most TAMs derive from circulating monocytes and can divide in some tumors (16, 17) . Chemotherapy with paclitaxel and carboplatin (Fig. 3I ) and immunotherapy with a small-molecule CSF-1R inhibitor ( fig. S22 ) also reduced CD169 + SCS macrophage density. Thus, the SCS macrophage barrier can be disrupted both during the natural course of tumor progression and upon anticancer treatment.
Because SCS macrophage-tEV interactions are geographically restricted to tdLNs, yet modulate the outgrowth of distant tumors, they may influence a systemic response to cancer. Indeed, depletion of CD169 + tdLN macrophages on one side only ( fig. S23 ) was sufficient to accelerate both contralateral and ipsilateral tumor growth (Fig. 4A) . We hypothesized that tEVs may bind and regulate discrete host components upon disruption of the SCS macrophage layer. Interestingly, tdLN multiphoton imaging revealed that, without SCS macrophages, tEVs efficiently penetrated the LN cortex (Fig. 4B) . These findings indicate that SCS macrophages act as tEV gatekeepers-a capacity that resembles these macrophages' ability to prevent the systemic spread of lymph-borne pathogens (15, (18) (19) (20) . Multiphoton imaging of tdLNs in SCS macrophagedepleted mice further revealed that tEVs reached B cell follicles (Fig. 4C) . Also, flow cytometrybased analysis of tdLNs identified B cells as the only detectable immune population physically interacting with tEVs in these mice (Fig. 4D and  fig. S24A ). Such interaction was lost in mice bearing Rab35S22N tumors, which are impaired to secrete tEVs ( fig. S24B) S24, C and D) . The concentration of tumorinfiltrating B cells also increased by a factor of 3 in SCS macrophage-depleted mice, whereas other immune cell populations remained detectably unchanged (Fig. 4E and fig. S25 ). To test a causal role for B cells in enhancing melanoma growth after CD169
+ LN macrophage ablation, we removed B cells by means of a CD20 mAb in DT-treated Cd169
Dtr/Wt mice. B cell ablation significantly decreased tumor progression in this experimental setting (Fig. 4F) . These data imply that B cells are tumor-promoting cells through tEV-B cell interactions that can be suppressed by SCS macrophages.
Because B cells may foster tumor progression by producing autoantibodies (21-23), we tested whether manipulating SCS macrophages modulates immunoglobulin G (IgG) responses. Indeed, CD169 + LN macrophage depletion amplified tdLN plasma cells ( fig. S26A ) and increased both plasma IgG concentration ( fig. S26B ) and IgG affinity for tumor antigens (fig. S26C ). The increased IgG concentration required full-fledged tEV secretion by tumors ( fig. S26D ). Most important, transfer of circulating IgGs from B16F10 tumor-bearing mice, in which SCS macrophages were depleted, significantly accelerated tumor growth in SCS macrophagecompetent mice (Fig. 4G and fig. S27 ). Thus, SCS macrophages can suppress cancer progression at least partly by limiting pro-tumor IgG responses (Fig. 4H) .
Our study identifies SCS macrophages as tumorsuppressive cells, in contrast to TAMs that often display tumor-promoting activities (24) . Yet tumor progression and at least some therapeutic agents undermine the SCS macrophage barrier, thereby enabling tEV interaction with B cells in the LN cortex and activating tumor-enhancing B cell immunity. Previous studies that investigated acute responses to pathogens and model foreign antigens had established that SCS macrophages can promote B cell responses (15, 20, (25) (26) (27) . The present data suggest that SCS macrophages can also provide a physical barrier to B cell activity under specific circumstances. It is possible that SCS macrophages acquire different functions when exposed continuously to inflammatory triggers or in the context of sterile inflammation. Additionally, tEVs may have unique properties that prevent their presentation by SCS macrophages to B cells or that alter SCS macrophage functions in vivo. Thus far, macrophage-targeting therapies to treat cancer are mostly aimed at depleting these cells indiscriminately (28) . Instead, our results favor therapeutic approaches that limit harmful TAM functions while leaving SCS macrophages unaffected. Whether it is possible to selectively expand SCS macrophages to control cancer also deserves consideration. In support of this scenario, a high density of CD169 + macrophages in regional LNs positively correlated with longer overall survival in patients with colorectal carcinoma (29) .
